The organochlorine (OC) sweetener sucralose is a synthetic trichlorinated disaccharide with the chemical name 1,6-dichloro-1,6-dideoxy-*β*-*D*-fructofuranosyl-4-chloro-4-deoxy-*α*-*D*-galactopyranoside (Merck Index, 2006). Its sweetness potency is approximately 385- to 650-fold higher than sucrose (table sugar) by weight, depending upon the specific food or beverage application ([@R95]; [@R333]; [@R338]). In 1991, sucralose was first approved for use in Canada, followed by Australia in 1993, and New Zealand in 1996 ([@R79]). In 1998, the U.S. Food and Drug Administration (FDA) approved sucralose for use in 15 food and beverage categories ([@R6]) that included water-based as well as fat-based products (e.g., frozen dairy desserts, baked goods, confections, puddings, chewing gum, fats and oils, beverages, and sugar substitutes such as Splenda). In 1999, the FDA expanded its approval beyond the original 15 categories for use as a general-purpose sweetener in all categories of foods and beverages ([@R24]). In 2004, sucralose (termed food additive E 955) was approved in the European Union (EU) in a variety of products including water- and fat-based desserts, certain alcoholic beverages, fat-based sandwich spreads, breakfast cereals, marinades, and chewing gum ([@R104]). Sucralose accounts for 27.9% of the \$1.146 billion global high-potency sweetener market ([@R227]) and is utilized in thousands of food, beverage, and pharmaceutical products in North America, Latin America, Europe, the Middle East, and the Asia-Pacific region ([@R130]; [@R79]). The range of product utilization is more extensive for sucralose than for other artificial sweeteners due to its physicochemical properties. For example, sucralose is readily soluble in ethanol, methanol, and water ([@R28]; [@R11]; Merck Index, 2006; [@R234]), and this solubility profile contributes to its versatility in both fat- and water-based food and beverage applications including alcoholic drinks. Other common artificial sweeteners such as aspartame, sodium saccharin, and acesulfame-potassium (ace-K) are only slightly or sparingly soluble in ethanol and*/*or methanol ([@R333]; Merck Index, 2006) and have more limited product applications. The Acceptable Daily Intake (ADI) level for sucralose was set at 5 mg*/*kg body weight per day (mg*/*kg*/*d) in the United States ([@R6]) and 15 mg*/*kg*/*d in the EU as recommended by Scientific Committee on Food of the European Commission ([@R342]), and there are no exclusions or restrictions for vulnerable population groups, including pregnant women, nursing mothers, infants, children, elderly, persons with medical conditions, and patients taking multiple medications.

Although sucralose is used globally in reduced-calorie and diet foods and beverages, issues regarding its biological effects and, therefore, its health profile have raised concerns. These issues include the following:

1.  *Effects of sucralose on glucose transport and other parameters involved in body weight regulation.* Sucralose modulates physiological parameters involved in normal body weight regulation, including faster intestinal glucose transport ([@R244], [@R245]) via interaction with sweet taste receptors located in the gastrointestinal tract (GIT) ([@R253]; [@R190]), increased insulin secretion via activation of sweet taste receptors on pancreatic ß cells ([@R274]), and altered sweet taste receptor expression in the hypothalamus ([@R318]) in rodents. Sucralose initiated the release of glucagon-like peptide-1 (GLP-1) in vitro ([@R190]; [@R253]), and ingestion of a sucralose-ace-K sweetened beverage increased GLP-1 secretion in healthy individuals as well as subjects with type 1 diabetes ([@R49]). GLP1 is an incretin hormone secreted in the gut that (1) induces glucose-dependent stimulation of insulin by the pancreas, (2) reduces glucagon secretion by the liver, (3) delays gastric emptying, and (4) increases satiety ([@R119]). Further, sucralose was shown to elevate glucose and insulin levels in a small study of obese women ([@R300]), who are at increased risk for further weight gain and development of diabetes.

2.  *Effects of sucralose on presystemic detoxification mechanisms and impact on bioavailability of therapeutic drugs.* Pharmacokinetic studies in animals and humans designed to characterize the metabolic fate of sucralose concluded that the majority of sucralose consumed (approximately 65--95% dependent on species) is not absorbed from the GIT but rather reportedly passes from the body unchanged in the feces ([@R142]; [@R195], [@R196]; [@R320]; [@R356]; [@R448]). The low reported bioavailability of this OC sweetener is unexpected given that it is an amphiphilic molecule ([@R171], [@R172]) with appreciable lipid solubility. The low absorption from the GIT suggested to [@R3] that sucralose might be actively recirculated into the intestinal lumen by the efflux transporter P-glycoprotein (P-gp) and*/*or metabolized by intestinal cytochrome P-450 (CYP) enzymes presystemically during first-pass metabolism. Both P-gp and CYP play major roles in the pharmacokinetics of a broad range of OC compounds as described in this review. [@R3] reported that sucralose (administered as the commercial sucralose product Splenda) at doses approved by the FDA and EU elevated the expression of P-gp and CYP enzymes in male rats to levels previously associated with significant reductions in the bioavailability of therapeutic drugs ([@R97]).

3.  *Metabolic fate and safety profile of sucralose metabolites.* Thin-layer chromatograms (TLC) of methanolic fecal extracts following sucralose administration to rats ([@R356]) and humans ([@R320]) revealed at least two closely eluting peaks that suggest sucralose is metabolized in the GIT. The identity and biological effects of the metabolites of sucralose associated with these peaks are not known at this time ([@R331]; [@R332]). The TLC data of [@R356] and [@R320] appear inconsistent with the claim that sucralose is not metabolized in the GIT as asserted by [@R142], [@R271], and [@R143].

4.  *Effect of sucralose on the number and relative proportions of different intestinal bacterial types.* Early studies of sucralose with bacteria in culture indicated that sucralose was not utilized as a carbon source by oral bacteria ([@R466]) or by bacteria from environmental samples ([@R220]). [@R3] extended these studies to bacteria cultured from the GIT of rats that had been administered sucralose daily. An overall reduction of the existing microflora was found (≥50%) at sucralose doses that were lower than the human ADI. Beneficial bacteria including lactobacilli and bifidobacteria were disproportionately affected compared to pathogenic bacteria including enterobacteria. Further, the reduction in fecal microflora was not fully reversible even 3 mo after cessation of sucralose. Sucralose was also reported to exhibit antimicrobial activity against two oral bacterial species involved in periodontal disease ([@R308]).

5.  *Potential toxicity from habitual sucralose ingestion.* Historical in vitro genotoxicity tests found that sucralose was weakly mutagenic in a mouse lymphoma mutation assay, and that one of its hydrolysis products was weakly mutagenic in both the Ames test and mouse lymphoma mutation assay ([@R159]; [@R6]). A subsequent comet test by [@R330] found that sucralose induced DNA damage in mouse GIT. Three independent labs showed that sucralose undergoes thermal decomposition at temperatures used in baking ([@R176]; [@R177]; [@R18]; [@R314]), and heating sucralose with glycerol, the backbone of triglycerides, generated chloropropanols, a potentially toxic class of compounds ([@R314]).

Each of these five issues is addressed in more detail in this review.

EFFECTS OF SUCRALOSE ON GLUCOSE TRANSPORT AND OTHER PARAMETERS INVOLVED IN BODY WEIGHT REGULATION {#s2}
=================================================================================================

Sucralose Modulates Physiological Processes Relevant to Body Weight {#s3}
-------------------------------------------------------------------

In the last several years, numerous studies in rodents reported that sucralose modulates physiological processes involved in nutrient absorption and body weight regulation via its interaction with sweet taste receptors (called T1R2/T1R3) located in enteroendocrine cells of the GIT ([@R190]; [@R253]), pancreatic ß cells ([@R274]), and the hypothalamus ([@R318]). Sucralose in vitro enhanced glucose-stimulated insulin secretion in the mouse insulinoma (ß cell) MIN6 line ([@R274]), isolated mouse islets ([@R274]), and isolated rat islets ([@R72]). Sucralose also initiated the release of glucagon-like peptide-1 (GLP-1) in several GIT model systems, including the human L cell line NCI-H716 ([@R190]) and mouse enteroendocrine cell line GLUTag ([@R253]). In vivo, oral ingestion of sucralose-sweetened water increased the expression of SGLT-1, the classical active Na^+^-glucose cotransporter, as well as glucose absorption in mice ([@R253]). Intestinal infusion of sucralose elevated glucose absorption via the diffusive apical GLUT2 pathway in rats ([@R244], [@R245]). However, sucralose given by oral gavage to rats in combination with an intraperitoneal (ip) glucose tolerance test exerted no marked effect on GLP-1 ([@R120]).

Although the majority of in vitro and in vivo studies in rodents detected significant effects of sucralose on physiological processes involved in nutrient absorption, findings of similar effects in humans have been inconsistent. Sucralose delivered in isolation (e.g., without co-administration of glucose) to human volunteers by oral ([@R115]) or by intragastric routes ([@R242]; [@R363]) exerted no marked effect on GLP-1. Oral consumption of sucralose without co-administration of glucose ([@R46]) produced no significant effect on blood glucose levels. Sucralose delivered by intraduodenal infusion in combination with glucose also exerted no marked effect on blood glucose or plasma GLP-1 ([@R243]). However, GLP-1 was elevated in human subjects (both in healthy volunteers and in individuals with type 1 diabetes) who drank a caffeine-free diet soda sweetened with sucralose and ace-K when compared with a carbonated water control; in both conditions subjects consumed the test solution (diet soda or carbonated water) 10 min prior to a glucose load ([@R48], [@R49]). Under similar test conditions, obese women displayed elevated glucose and insulin levels when exposed to sucralose alone ([@R300]). Recent animal data suggest that habitual oral ingestion of high-potency sweeteners that do not provide calories may blunt GLP-1 release and produce hyperglycemia in response to subsequent oral glucose tolerance tests ([@R378]).

[@R318] found that sucralose modulated the expression of the gene for the sweet taste receptor *T1R2* in cells from the hypothalamus, a nutrient-sensing region of the brain, in rodents. Data showed that *T1R2* expression was elevated when the hypothalamic cells were exposed to low (compared to high) extracellular glucose concentrations, and this was reversed with addition of sucralose to the low-glucose medium. That is, addition of sucralose resulted in expression levels of *T1R2* that would be expected if higher extracellular glucose levels were actually present. Thus, activation of the sweet taste receptor in the brain by nonnutritive sucralose might potentially affect appetite regulation by providing an inaccurate signal regarding the actual levels of extracellular glucose in the brain ([@R331]). However, it is not yet known if the portion of sucralose that is absorbed into the systemic circulation can traverse the blood--brain barrier to reach the hypothalamus.

Association Between Artificial Sweetener Use, Body Weight, and Obesity {#s4}
----------------------------------------------------------------------

Major contributors to the rising obesity epidemic are excess consumption of energy-dense foods and reduced physical activity ([@R159]). Many additional factors have also been reported to contribute to the obesity epidemic, including OC compound exposure, use of artificial sweeteners, consumption of soft drinks (both sugar-sweetened and diet), alterations of the microbiome, use of medications, epigenetic changes due to an obesogenic environment in utero, environmental exposure to endocrine disruptors, indoor air conditioning, and chronic sleep deprivation ([@R66]; [@R218]; [@R80]; [@R35]; [@R379]). For many years, exposure to OC pesticides including lindane ([@R56]), DDT ([@R81]), aldrin ([@R81]), and hexachlorobenzene ([@R418]) was associated with elevated body weight gain in rodent models. In humans, prenatal exposure to DDE (dichlorodiphenyl-dichloroethylene), a metabolite of DDT, was linked to increased body weight of female offspring ([@R200]). In addition, the prevalence of diabetes in humans has been positively correlated to OC exposure ([@R228]; [@R306]; [@R415]). Epidemiological studies in humans ([@R116]; [@R364]; [@R86]; [@R241]; [@R460]) and lab studies in animals ([@R376]; [@R377], [@R379]) both suggest an association between use of artificial sweeteners and body weight gain. Epidemiological studies also demonstrated that artificial sweetener use increased the risk for metabolic syndrome, type 2 diabetes, hypertension, and cardiovascular disease ([@R375]). Most human epidemiological studies have not distinguished among the different types of artificial sweeteners (e.g., sucralose, saccharin, acesulfame-K, aspartame, neotame, stevioside, and rebaudioside) but rather treated them as a group. One exception is the Nurses' Health Study cohort ([@R70]), which did specifically associate saccharin use with weight gain. This finding is consistent with recent animal experiments ([@R376]; [@R377]) in which saccharin intake was related to weight gain in rats. Because OC compounds and artificial sweeteners have both been associated with weight gain, and because sucralose is a member of both categories, it is important to determine its effect on mechanisms that regulate body weight.

Effect of Sucralose on Body Weight in Humans {#s5}
--------------------------------------------

To date, the effect of chronic oral consumption of sucralose on body weight at levels approved by the FDA and EU has not been studied prospectively in adults. In a lab setting, ingestion of sucralose tends to increase intake after a 60-min interval ([@R10]); however, it is not yet known whether this finding transfers into chronic body weight gain in free-living adult populations. In an 18-mo trial with children, participants were randomly assigned to receive an 8-oz can per day of either a noncalorically sweetened or a sugar-sweetened beverage that provided 104 kcal ([@R83]). Each can of sugar-free beverage contained 34 mg sucralose and 12 mg acesulfame-K, and the mean sucralose dosage for the sugar-free group was 1.1 mg/kg/d. The mean duration of the study was 541 d (77.3 wk), during which 477 of 641 children completed the intervention by consuming an average of 5.8 beverages per week. Measurement of urinary sucralose levels was one of several markers used to monitor compliance with the protocol. The calorie consumption from these beverages was 46,627 kcal greater for children in the sugar-sweetened group than in the sucralose-sweetened group (5.8 × 77.3 × 104). In spite of this highly significant difference in calories consumed from the beverages, the total weight gain over this 18-mo study was only 1 kg greater for children in the sugar-sweetened group compared to sucralose group. No explanation was provided to account for the small difference in weight gain given the large difference in caloric consumption from the beverages. However, one possible explanation is that the children who consumed the sugar-sweetened beverages compensated by reducing their food intake. A control group that ingested water as a comparison was not included. Another study in adolescents showed no consistent reduction of weight gain at a 2-year follow-up when their families were supplied with artificially sweetened beverages in order to reduce their consumption of sugar-sweetened sodas ([@R98]).

Effect of Sucralose on Body Weight in Animals {#s6}
---------------------------------------------

In rats, a sucralose dosage of 1.1 mg/kg/d (equivalent to that provided to children by [@R83]) produced a significant body weight gain (10.9% greater than controls) over a 12-wk period ([@R3]). However, weight gain relative to control was not observed in rats at higher dosages of 3.3, 5.5, and 11 mg/kg/d sucralose. After a 12-wk recovery period from sucralose treatment, there were significant increases in body weight for rats previously treated with sucralose relative to control animals for 2 of 4 sucralose dosage groups. After recovery from 1.1 mg/kg/d, there was a 17.1% rise in body weight relative to control animals, and after recovery from 5.5 mg/kg/d, a 21.3% elevation. In the human nutrition literature, a weight difference ≥5% is considered clinically significant ([@R444]). Two possible explanations (described in more detail later in this review) for the significant body weight gain at the lowest (not highest) dosage of sucralose by the end of treatment period include: (1) Sucralose may no longer be bioavailable as an intact molecule at higher dosages due to increased intestinal expression of (and metabolism by) CYP enzymes, and (2) intestinal bacteria that normally reclaim calories from undigested dietary nutrients in the intestines are suppressed to a greater degree at the higher dosages. The finding of a weight gain after a 12-wk recovery from sucralose may be due to a partial rebound in the number of bacteria that ferment complex dietary carbohydrates to form short-chain fatty acids that are subsequently absorbed.

Animal data regarding body weight gain reported in historical subchronic and chronic toxicity studies utilized sucralose dosages that far exceed levels approved for use in foods by the FDA ([@R6]) and [@R104], and the results on body weight gain in these toxicity studies are inconsistent and conflicting. Increases in mean body weight gain were found in sucralose-treated beagle dogs relative to controls at 0.3 to 3% of the diet (approximately 90 to 900 mg/kg/d respectively), and this weight gain was accompanied by a rise in food consumption ([@R131]). Body weight gain in rats, however, appeared to be dependent in part on the route of delivery of sucralose. Rats that consumed high doses of sucralose in toxicity tests by the oral route (dietary administration) showed significant decreases in body weight gain relative to controls in spite of relatively small reductions in food consumption. These disproportionately large declines in body weight gain despite only small decreases in intake were attributed to low palatability of sucralose at high concentrations. Body weight changes in rats that received high dosages of sucralose by gavage (which circumvents taste issues associated with dietary administration of an unpalatable test material) were variable with losses, gains and no marked changes reported ([@R131]; [@R6]). These animal feeding results are not directly transferable to humans, however, because the dosages delivered to animals in these toxicity tests were significantly higher than usage levels approved for humans.

Learned Associations and High-Potency Sweeteners as a Group {#s7}
-----------------------------------------------------------

A learning paradigm has been proposed to explain how high-potency sweeteners as a group may influence body weight regulation and glucose homeostasis ([@R379], [@R378]; [@R375]). This paradigm is based on the principle that humans and non-human animals learn the relationships between the sensory properties of foods (e.g., taste, smell, texture) and their postingestive nutritive consequences to maintain energy balance ([@R436]; [@R376]; [@R377], [@R379]). Throughout evolutionary history (at least until the recent introduction of high-potency sweeteners), learned sweet taste cues have been reliable predictors of the energy density of food. However, the introduction of high-potency sweeteners that have negligible utilizable calories into the food supply reduced the validity of sweet taste as a signal for calories. Uncoupling the relationship between sensory properties of foods and their caloric content was shown to contribute to weight gain in rats ([@R436]). Using learning paradigms with a rat model, Swithers and colleagues ([@R376]; [@R377], [@R379]) found that consumption of foods and fluids containing high-potency sweeteners (saccharin, acesulfame-K, and/or steviol glycosides were used in these experiments) interfered with the ability of sweet taste to predict caloric consequences and thus disrupted energy regulation. Further, the nonpredictive sweet--calorie relationship was persistent and difficult to reverse even after predictive sweet--calorie training with glucose ([@R377]). Thus, exposing rats to high-potency sweeteners degraded the consistent and predictive relationship between taste, energy intake, and body weight regulation.

The degree to which these animal-learning studies of sweeteners can be extrapolated to humans and to sucralose in particular has not yet been determined. Humans can distinguish among many different sweetener types by taste ([@R337], [@R335], [@R334]; [@R333]), and functional magnetic resonance (fMRI) imaging studies also indicate that the human brain signals distinguish caloric sweeteners (e.g., sucrose) from noncaloric sweeteners (e.g., sucralose and saccharin) ([@R117]; Haase et al., 2008). However, neuroimaging studies by [@R325] revealed that routine use of high-potency sweeteners as a group altered brain responses to sucrose in the amygdala and insula as determined by fMRI scanning. Data suggested that these alterations in brain activity were due to degradation or uncoupling of the predictive relationship between sweet taste and its postingestive consequences, as reported previously in rat models ([@R379]). The findings of [@R325] are consistent with those of [@R140], who reported that higher order reward regions of the brain are activated to a greater extent by sweeteners in young adult diet-soda drinkers compared to nondrinkers. These brain imaging studies in conjunction with epidemiological data that associate artificial sweetener use with weight gain suggest that high-potency sweeteners interfere with learned sweet--calorie relationships in humans as well as animals ([@R375]).

Effect of Sucralose in Patients With Diabetes {#s8}
---------------------------------------------

A study of patients with diabetes ([@R144]) reported no significant effect of sucralose on glycosylated hemoglobin (HbA1c) as a marker of the average plasma glucose concentrations over approximately 3 mo. [@R144] instructed patients with diabetes to self-administer capsules of sucralose twice daily over a 3-mo period; however, data on compliance with self-administration (e.g., urinary sucralose levels) and body weight changes were not reported. Daily supervision of capsule administration, rather than self-administration, is scientifically prudent for studies of patients with diabetes because noncompliance with treatment regimens is reportedly high in this population ([@R456]). Further, no apparent information of dissolution characteristics of the capsule was provided; thus, it is unknown where sucralose was released in the GIT. Future studies of sucralose on diabetes management will require randomized trials that are carefully supervised and control for the variables involved.

EFFECTS OF SUCRALOSE ON PRESYSTEMIC DETOXIFICATION MECHANISMS AND IMPACT ON BIOAVAILABILITY OF THERAPEUTIC DRUGS {#s9}
================================================================================================================

Background: Role of Intestinal Transporters and CYP Metabolizing Enzymes in Bioavailability of Xenobiotics {#s10}
----------------------------------------------------------------------------------------------------------

Orally administered xenobiotics such as therapeutic drugs and artificial food additives reach the small intestine, where they cross the intestinal membranes to be transported into the hepatic portal system and ultimately to the systemic circulation. During their transit from the GIT to the systemic circulation, xenobiotics interact with metabolic enzymes and transporters in the GIT and liver that limit their systemic bioavailability. The decrease in the concentration of a xenobiotic compound as it passes through the GIT and liver is termed the "first-pass effect" ([@R319]; [@R188]; [@R351]; [@R438]; [@R292]; [@R291]). The intestinal component of the first-pass effect is especially significant in the disposition of sucralose because the majority of this OC sweetener is reportedly unabsorbed from the small intestine after ingestion ([@R142]) even though it is an amphiphilic compound with appreciable lipid solubility ([@R171]; [@R172]; [@R11]; [@R234]). Further, higher doses of orally administered sucralose in humans are associated with lower urinary excretion that suggests sucralose absorption is reduced at increased concentrations ([@R320]). The findings by [@R3] described in the next section suggest that the efflux transporter P-gp and metabolism by intestinal CYP limit oral absorption of sucralose (and/or its metabolites) from the GIT. P-gp is an energy-dependent "pump" that is highly expressed at the luminal surface of enterocytes ([@R237]; [@R252]). It is a member of the ATP-binding cassette (ABC) transporter superfamily and a product of the *ABCB1* gene (also known as *MDR1*). P-gp serves as a barrier to harmful chemicals (as well as many therapeutic drugs) by transporting them out of enterocytes, back into the intestinal lumen ([@R360]; [@R254]; [@R446]; [@R372]; [@R91]; [@R4]; [@R106]). P-gp interacts with many structurally diverse hydrophobic and amphiphilic compounds ([@R122]; [@R252]; [@R461]) including OC drugs ([@R305]; [@R44]; [@R430]; [@R431]; [@R432]) and OC pesticides ([@R16]).

Intestinal metabolism by members of the CYP superfamily of heme-containing enzymes contributes significantly to the first-pass effect ([@R213]; [@R437], [@R438]; [@R294], [@R293]; [@R395]; [@R221]; [@R151]; [@R424]; [@R420]). The CYP superfamily is divided into families (including CYP1, CYP2, and CYP3, which are responsible for metabolism of drugs and xenobiotics) and into subfamilies labeled with a letter, such as CYP3A or CYP2D. CYP3A has a broad substrate specificity and is a predominant isoform of CYP expressed in the upper intestine ([@R439]; [@R214]; [@R146]; [@R471]; [@R268]; [@R384]; [@R257]). Organochlorine drugs such as midazolam undergo significant intestinal metabolism by the CYP3A subfamily ([@R294]; [@R396]; [@R163]; [@R52]). The catalytic activities of intestinal and hepatic CYP3A are independently regulated so that measures of CYP-mediated metabolism of xenobiotics in the liver do not necessarily predict the effects of CYP-mediated metabolism in the intestine ([@R150]; [@R240]; [@R7]; [@R292]; [@R414]).

Although the roles of P-gp and CYP in limiting the bioavailability of xenobiotics are different, there is significant overlap in compounds that are effluxed by P-gp and those metabolized by CYP3A ([@R438]; [@R425], [@R424], [@R340]; [@R26]). While P-gp effluxes xenobiotics back into the intestinal lumen, CYP enzymes promote elimination of xenobiotics through oxidation and reduction reactions that render chemicals more polar and water-soluble. Studies of xenobiotic detoxification and clearance indicate that co-localization of P-gp and CYP3A within enterocytes facilitates an interactive process by which the bioavailability of compounds that are dual P-gp/CYP3A substrates is reduced. P-gp enhances presystemic metabolism in the intestine by increasing the duration of exposure to CYP3A via repeated efflux and reabsorption into enterocytes. This repetitive recycling process that engages both intestinal P-gp and CYP3A provides a barrier to absorption ([@R27]), and may account for the low systemic oral bioavailability of sucralose.

Splenda (Active Ingredient: Sucralose) Increases the Expression of Intestinal P-gp and Two CYP Isoforms {#s11}
-------------------------------------------------------------------------------------------------------

[@R3] reported that Splenda, a commercially available form of sucralose, increased the expression of intestinal P-gp and CYP in male Sprague-Dawley rats. Splenda contains the high-potency OC sweetener sucralose along with the fillers, maltodextrin and glucose. Splenda was administered for 12 wk by oral gavage at sucralose dosages equivalent to 0 (vehicle control), 1.1, 3.3, 5.5, or 11 mg/kg/d. All sucralose dosages tested fell below the ADI approved for use in the food supply by the European Union ([@R104]). The two lower dosages fell below the ADI for sucralose approved by the [@R407]. After 12 wk, half of the animals from each group were sacrificed to measure the expression of intestinal P-gp, CYP3A, and CYP2D in the jejunum and ileum. The other half of the animals were allowed to recover from treatment (no Splenda) for another 12 wk, after which expression of intestinal P-gp, CYP3A, and CYP2D was again measured. P-gp and CYP expression were assessed using antibodies that detected P-gp, CYP3A protein, and CYP2D1, the rat isozyme analogous to human CYP2D6 ([@R225]). These antibodies were selected because the CYP3A and CYP2D subfamilies are collectively involved in the metabolism of more than 70% of medications ([@R78]; [@R110]; [@R184]).

[Table 1](#T1){ref-type="table"} shows the changes in P-gp and CYP expression relative to control (vehicle, no Splenda) after daily treatment at each of 4 dosage levels for 12 wk. At the lowest dose (1.1 mg/kg/d sucralose), there was no significant change in the expression of P-gp or CYP. However, at 3.3 mg/kg/d sucralose, there was a marked increase in P-gp as well as significant elevation in CYP. \[Note: For a 130-lb (58.9 kg) woman, the 3.3-mg/kg/d dosage of sucralose is equivalent to approximately two 12-oz (340 g) servings of a diet soda. For a 70-lb (31.8 kg) child, the 3.3-mg/kg/d dosage is equivalent to only one 12-oz (340 g) serving.\] At 5.5 mg/kg/d sucralose delivered in Splenda, the expression of P-gp and CYP remained elevated with expression of CYP growing in magnitude with increasing dosage. \[Note: For a 130-lb woman, the 5.5-mg/kg/d dosage is equivalent to approximately two 12-oz (340 g) servings of a sucralose-sweetened soft drink and two pieces of sucralose-sweetened cake.\] At 11 mg/kg/d sucralose, expression of P-gp decreased significantly rather than increasing, while CYP expression continued to rise. Residual effects on P-gp and CYP expression at some dose levels remained at the end of the 12-wk recovery period in the absence of Splenda. Thus, Splenda enhanced the expression of P-gp and CYP at sucralose dosages commonly ingested by consumers, and some changes in expression persisted 3 mo after cessation of intake.

###### 

Significant Changes in the Expression of P-gp, CYP3A, and CYP2D Subsequent to Sucralose Ingestion (Delivered in Splenda) Relative to Control (No Sucralose) in Rat

              Sucralose dosage (mg/kg/d)   P-gp     CYP3A    CYP2D
  ----------- ---------------------------- -------- -------- --------
  Treatment   1.1                          ---      ---      ---
              3.3                          ↑        ↑        ↑
                                           143.5%   43.5%    36.7%
              5.5                          ↑        ↑        ↑
                                           122.6%   70.0%    152.1%
              11                           ↓        ↑        ↑
                                           64%      151.3%   249.3%
  Recovery    1.1                          ---      ---      ---
              3.3                          ↑        ---      ---
                                           16%               
              5.5                          ↑        ---      ↑
                                           56.8%             32.9%
              11                           ↑        ↑        ↑
                                           82.2%    22.4%    22.1%

*Note.* Data from [@R3].

The results in [Table 1](#T1){ref-type="table"} indicate that the magnitude of elevation for both CYP3A and CYP2D expression increased in a linear, dose-dependent manner as the dosage of sucralose increased from 3.3 to 5.5 to 11 mg/kg/d. This finding of significant and parallel increases in expression of two different CYP enzymes does not support the claim made by [@R51] that increases in CYP from sucralose ingestion were only normal biological variations. Significant changes in P-gp expression, like CYP expression, also occurred at sucralose dosages 3.3, 5.5, and 11 mg/kg/d; however, the magnitude of the elevation of P-gp expression was maximum at 3.3 mg/kg/d sucralose and decreased monotonically at increasing dosages; that is, as CYP expression rose, P-gp expression decreased. Two possible explanations for this relationship between CYP and P-gp are the following. First, [@R3] and [@R332] suggested that the dose-dependent rise in CYP expression increased the metabolism of sucralose and reduced the concentration of intact sucralose molecules in the GIT. At an oral dosage of 11 mg/kg/d, the concentration of intact sucralose in the GIT was reduced to levels that were insufficient to elevate the expression of P-gp. Second, saturation of P-gp may have occurred as the dosage of sucralose increased. Nonlinear pharmacokinetics, including saturation, is characteristic of the intestinal component of the xenobiotic metabolism ([@R381]; [@R386]; [@R155]; [@R329]; [@R324]).

The rise in CYP expression reported by [@R3] may result from "autoinduction," by which sucralose enhances it own metabolism. Autoinduction is a well-known biological phenomenon by which xenobiotics induce proteins involved in their own detoxification ([@R340]). Autoinduction of CYP isozymes was reported after administration of both OC ([@R476]; [@R57]) and non-organochlorine ([@R32], [@R33]; [@R371]; [@R370]; [@R60]) drugs. The fillers in Splenda did not contribute to the expression of P-gp and CYP enzymes because glucose (as well as the maltodextrin component, which is hydrolyzed to glucose) is rapidly absorbed in the duodenum ([@R40]). The expression of P-gp and CYP was quantified by [@R3] in the jejunum and ileum rather than the duodenum because P-gp expression is greater in the more distal region of the small intestine ([@R182]). [@R3] postulated that the elevated expression of intestinal P-gp and CYP subsequent to sucralose ingestion may increase the clearance of co-administered medications (and hence reduce their bioavailability) due to the critical role of P-gp and CYP in the pharmacokinetics of therapeutic drugs ([@R77]; [@R354]). An example is the upregulation of P-gp and CYP by St. John\'s wort, which led to renal transplant rejections due to sub-therapeutic levels of the immunosuppressant cyclosporine ([@R21]).

The findings of increased intestinal expression of P-gp and CYP by [@R3] do not support claims by [@R143] and [@R51] that CYP is not induced by sucralose. These claims were based on an unpublished report in 1987 that trichlorogalactosucrose, the previous name for sucralose, did not induce hepatic CYP expression in rats ([@R159]). However, no methodological descriptions, data, or results from this report have been published in the peer-reviewed literature. Further, lack of hepatic induction does not preclude induction of intestinal CYP, because, as noted previously, the correlation between intestinal and hepatic metabolic rates in both rats and humans is low ([@R7]; [@R240]).

Splenda Effects on P-gp and CYP Are Consistent With the Literature on Other Organochlorine Compounds {#s12}
----------------------------------------------------------------------------------------------------

The finding by [@R3] that the sucralose (delivered as Splenda) interacts with efflux and metabolizing proteins is consistent with an extensive scientific literature that indicates OC compounds characteristically interact with CYP (and in some cases P-gp). [Table 2](#T2){ref-type="table"} provides a list of 89 representative OC therapeutic drugs; all of these drugs were shown to interact with CYP (and some with P-gp) as substrates, inhibitors, and/or inducers. A given drug may act as an inhibitor or inducer (as well as a substrate) depending on a variety of factors, including drug concentration and time course ([@R256]). The most frequent interactions for OC drugs in [Table 2](#T2){ref-type="table"} were with CYP3A (62%) and CYP2D (36%), that is, members of the same two subfamilies of CYP involved in the disposition of sucralose ([@R3]). Although the majority of the drugs in [Table 2](#T2){ref-type="table"} were substrates of CYP and/or P-gp, some of these OC drugs, like sucralose, were reported to increase CYP and/or P-gp expression. The OC drugs midazolam ([@R340]), nefazodone ([@R5]), trazodone ([@R367]), clotrimazole ([@R340]), and efavirenz ([@R44]) were reported to be inducers of P-gp. The OC drugs clotrimazole ([@R340]), griseofulvin ([@R462]), and efavirenz ([@R113]) were found to be inducers of CYP3A. Both P-gp and CYP3A were induced by clotrimazole and efavirenz.

###### 

Representative Organochlorine Drugs Reported to Be Substrates, Inhibitors, or Inducers of CYP isozymes and/or P-gp Using One or More Assay Types

  Drug types                           Interactions with CYP and/or P-gp   References
  ------------------------------------ ----------------------------------- ----------------------------------------------------------------------
  *Anticancer drugs*                                                       
  Cyclophosphamide                     CYP                                 [@R231]; [@R302]; [@R23]; [@R57]
  Ifosfamide                           CYP                                 [@R231]; [@R302]; [@R23]; [@R57]
  Lomustine                            CYP                                 [@R150]
  Sorafenib                            CYP, P-gp                           [@R112]; [@R174]
  Toremifene                           CYP, P-gp                           [@R31]; [@R317]
  Trofosfamide                         CYP                                 [@R151]
  *Cardiovascular and related drugs*                                       
  Amlodipine                           CYP, P-gp                           [@R113]; [@R203],[@R204]
  Clofibrate                           CYP                                 [@R55]; [@R6]; [@R309]
  Clopidogrel                          CYP                                 [@R146]; [@R279]
  Felodipine                           CYP, P-gp                           [@R113]; [@R146]; [@R430]
  Fenofibrate                          CYP, P-gp                           [@R113]; [@R210]; [@R100]; [@R266]
  Guanabenz                            CYP                                 [@R68]
  Losartan                             CYP, P-gp                           [@R113]; [@R146]; [@R359]
  Ticlopidine                          CYP                                 [@R113]; [@R279]; [@R180]
  Tienilic acid                        CYP                                 [@R191]
  *Anti-inflammatory drugs*                                                
  Aceclofenac                          CYP                                 [@R43]
  Diclofenac                           CYP                                 [@R388]; [@R42]; [@R113]; [@R186]
  Indomethacin                         CYP                                 [@R113]; [@R440]
  Lornoxicam                           CYP                                 [@R113]; [@R148]
  *Anti-infective drugs*                                                   
  Amodiaquine                          CYP                                 [@R10]: [@R113]; [@R19]
  Atovaquone                           CYP                                 [@R413]
  Chloramphenicol                      CYP                                 [@R113]; [@R297]
  Chloroquine                          CYP, P-gp                           [@R355], [@R311], [@R305]
  Clofazimine                          CYP, P-gp                           [@R309]; [@R430]
  Clotrimazole                         CYP, P-gp                           [@R186]; [@R340]; [@R90]; [@R427]; [@R472]; [@R124]; [@R16]; [@R108]
  Econazole                            CYP                                 [@R392]
  Flucloxacillin                       CYP, P-gp                           [@R178]
  Griseofulvin                         CYP                                 [@R462]
  Halofantrine                         CYP                                 [@R113]; [@R355]; [@R24]
  Itraconazole                         CYP, P-gp                           [@R186]; [@R113]; [@R231]; [@R431]; [@R385]; [@R270]
  Ketoconazole                         CYP, P-gp                           [@R186], [@R231]; [@R113]; [@R383]; [@R430], [@R431]; [@R65]
  Miconazole                           CYP, P-gp                           [@R186]; [@R472]; [@R101]; [@R341]
  Niclosamide                          CYP                                 [@R19]
  Oxiconazole                          CYP                                 [@R373]
  Proguanil                            CYP                                 [@R113]; [@R169]; [@R19]; [@R146]
  *Psychotropic drugs*                                                     
  Adinazolam                           CYP                                 [@R416]
  Alpidem                              CYP                                 [@R30]; [@R277]; [@R146]
  Alprazolam                           CYP                                 [@R113]; [@R464]; [@R475]
  Aripiprazole                         CYP                                 [@R423], [@R113]; [@R156]
  Brotizolam                           CYP                                 [@R399]
  Bupropion                            CYP                                 [@R113]; [@R107]; [@R215]
  Chlordiazepoxide                     CYP, P-gp                           [@R401]; [@R236]
  Chlormethiazole                      CYP                                 [@R186]
  Chlorpromazine                       CYP, P-gp                           [@R465]; [@R113]; [@R231]; [@R44]; [@R179]
  Clobazam                             CYP                                 [@R129]
  Clomipramine                         CYP, P-gp                           [@R121]; [@R113]; [@R179]; [@R126]
  Clonazepam                           CYP                                 [@R231]
  Clotiazepam                          CYP                                 [@R280]
  Clozapine                            CYP, P-gp                           [@R310]; [@R287]; [@R113]; [@R303]; [@R231]; [@R179]
  Diazepam                             CYP, P-gp                           [@R121]; [@R113]; [@R289]; [@R236]
  Estazolam                            CYP                                 [@R269]
  Eszopiclone                          CYP                                 [@R273]
  Haloperidol                          CYP, P-gp                           [@R121]; [@R113]; [@R231]; [@R179]; [@R187]; [@R216]
  Midazolam                            CYP, P-gp                           [@R113]; [@R135]; [@R400]; [@R340]; [@R383]
  Moclobemide                          CYP                                 [@R39]; [@R113]
  Nefazodone                           CYP, P-gp                           [@R186]; [@R113]; [@R367]
  Nordiazepam                          CYP                                 [@R289]
  Perphenazine                         CYP                                 [@R186]; [@R113]; [@R286]
  Sertindole                           CYP                                 [@R310]; [@R146]
  Sertraline                           CYP, P-gp                           [@R113]; [@R283]; [@R442]; [@R432]
  Temazepam                            CYP                                 [@R289]
  Trazodone                            CYP, P-gp                           [@R113]; [@R323]; [@R246]; [@R126]; [@R367]; [@R443]
  Triazolam                            CYP                                 [@R113]; [@R419]; [@R288]
  Ziprasidone                          CYP                                 [@R113]; [@R307]
  Zopiclone                            CYP                                 [@R24]
  Zotepine                             CYP                                 [@R352]
  Zuclopenthixol                       CYP                                 [@R121]; [@R113]
  *Anesthestics*                                                           
  Enflurane                            CYP                                 [@R207]; [@R113]
  Halothane                            CYP                                 [@R362]; [@R113]
  Isoflurane                           CYP                                 [@R207]; [@R113]
  Ketamine                             CYP                                 [@R164]
  Methoxyflurane                       CYP                                 [@R207]; [@R113]
  *Antihistamines*                                                         
  Azelastine                           CYP, P-gp                           [@R275],[@R276]; [@R205]
  Chlorpheniramine                     CYP                                 [@R113]; [@R463]; [@R152]
  Clemastine                           CYP                                 [@R113]; [@R152]
  Desloratadine                        CYP, P-gp                           [@R309]; [@R58]
  Hydroxyzine                          CYP, P-gp                           [@R113]; [@R152]; [@R198]
  Loratadine                           CYP, P-gp                           [@R45]; [@R127]; [@R58]
  *Muscle relaxants*                                                       
  Chlorzoxazone                        CYP                                 [@R136]; [@R113]
  Tizanidine                           CYP                                 [@R139]; [@R113]
  *Other*                                                                  
  Anagrelide                           CYP                                 [@R426]
  Chlorpropamide                       CYP                                 [@R353]
  Cisapride                            CYP                                 [@R84]; [@R113]
  Domperidone                          CYP, P-gp                           [@R113]; [@R434]; [@R246]; [@R105]; [@R339]
  Efavirenz                            CYP, P-gp                           [@R113]; [@R217]; [@R282]; [@R368]
  Glibenclamide                        CYP, P-gp                           [@R113]; [@R235]; [@R473]; [@R133]
  Loperamide                           CYP, P-gp                           [@R209]; [@R5]; [@R429]; [@R339]; [@R305]
  Metoclopramide                       CYP, P-gp                           [@R113]; [@R85]; [@R89]
  Montelukast                          CYP                                 [@R113]; [@R428]

P-gp and CYP also play a role in the disposition of nonpharmaceutical OC compounds such as OC pesticides, herbicides, and other industrial chemicals. Pesticides such as chlorpyrifos, tetrachlorohydroquinone, chlordecone, heptachlor, chlorthiophos, dicapthon, fluvalinate, and permethrin interact with P-gp ([@R223]; [@R16]). Organochlorine insecticides and pesticides that are metabolized by CYP isozymes include chlorpyrifos ([@R387]), *p,p*'-DDT \[1,1,1-trichloro-2,2-*bis*(*p*-chlorophenyl)ethane\] ([@R1]; [@R2]; [@R211]), and methoxychlor ([@R175]). The herbicides acetochlor, butachlor, and metolachlor are metabolized by CYP ([@R71]), as are many industrial OC compounds ([@R134]) including chlorinated benzenes ([@R38]), chloroform ([@R125]), chlorofluorocarbons ([@R82]), and trichloroethylene ([@R239]). Similar to OC drugs, OC pesticides and industrial compounds may be inducers and inhibitors of CYP in addition to being substrates ([@R296]; [@R73]). Overall, the preponderance of data indicates that P-gp and CYP are routinely involved in the disposition of a vast array of OC compounds including drugs, pesticides, and industrial chemicals, as well as the OC sweetener sucralose.

Additional Intestinal Transporters and CYP Isozymes May Be Involved in the Disposition of Sucralose {#s13}
---------------------------------------------------------------------------------------------------

The finding that only a fraction of relatively high concentrations of ingested sucralose is absorbed from the intestine raises the possibility that efflux transporters or CYP isozymes, in addition to P-gp, CYP3A, and CYP2D, may play a role in limiting the bioavailability of sucralose ([@R29]; [@R77]; [@R103]; [@R354]; [@R46], for reviews of efflux and uptake transporters). Organochlorine drugs such as clotrimazole and glibenclamide were shown to interact with numerous types of efflux transporters at physiological barriers including the intestine (and liver, kidney, and blood--brain barrier). The antifungal drug clotrimazole is an inducer of MRP2 (multidrug resistance-related protein 2) ([@R206]), and the antidiabetic drug glibenclamide is a substrate of the efflux transporter BCRP (breast cancer resistance protein) ([@R123]). MRP2 and BCRP, like P-gp, are members of the ABC transporter superfamily and shunt substrates out of the cytoplasm of eukaryotic cells, including enterocytes. In order to determine and identify transporters in addition to P-gp that may play a role in the disposition of sucralose, testing strategies similar to those utilized in pharmaceutical research ([@R185]) can be applied. Evaluation of CYP isoforms in addition to the subfamilies CYP3A and CYP2D may also be warranted to determine which other CYP subfamilies also contribute to sucralose metabolism.

General Mechanisms Responsible for Increases in P-gp and CYP Expression {#s14}
-----------------------------------------------------------------------

Increases in P-gp and CYP expression result from modulation of gene transcription as well as from posttranscriptional and posttranslational modification ([@R212]; Handschin and Meyer, 2004; [@R255]; [@R61]). Increased expression of both P-gp and CYP3A occurs through a sequence of steps involving transcriptional activation of genes (initiated by nuclear receptors including the pregnane X receptor, PXR) followed by enhanced production of messenger RNA (mRNA) and protein synthesis ([@R212]; [@R255]). PXR is a xenobiotic sensor that is directly activated by xenobiotic (including OC) compounds. PXR coordinately upregulates genes and induces the expression of proteins involved in detoxification (including P-gp and CYP3A); this results in levels of transporters and metabolic proteins that are in excess of those normally present. PXR plays a major role in the induction of CYP3A from exposure to OC pesticides, such as DDT, chlordane, dieldrin, and endosulfam, as well as OC drugs such as clotrimazole ([@R181]; [@R73]). Unlike induction of P-gp and CYP3A, the CYP2D subfamily has traditionally been considered refractory to induction via gene activation involving nuclear receptors ([@R184]). While enhanced expression and activity of CYP2D occur in humans, monkeys, and rodents after exposure to drugs and herbs ([@R272]; [@R162]; [@R113]; [@R265]; [@R435]; [@R467]; [@R248]), this elevated expression was typically attributed to posttranscriptional events such as increased translation efficiency or stabilization of protein ([@R467]). In summary, our current state of knowledge suggests that the predominant mechanism responsible for increased expression of P-gp and CYP3A from sucralose ingestion is transcriptional activation involving PXR, while the enhanced expression of CYP2D occurs via a posttranscriptional mechanism.

Factors in addition to PXR, such as activation of taste receptors and microRNAs, may also contribute to increased expression of P-gp and CYP3A from sucralose ingestion. Induction of P-gp was reported in intestinal cells via signaling from gut "taste" receptors ([@R192]). In addition, OC compounds can interact with microRNAs ([@R398]), and recent studies indicate that microRNAs are involved in the regulation of CYP3A enzymes ([@R382]; [@R295]). Nuclear mechanisms in addition to PXR activation may also play a role in P-gp and CYP3A induction ([@R295]; [@R380]).

Potential Adverse Sucralose--Drug Interactions {#s15}
----------------------------------------------

The increased expression of P-gp and CYP in rats reported by [@R3] raises the possibility of potential adverse sucralose-drug interactions in humans. The scientific literature on drug--drug interactions indicates that the magnitude of the elevated expression of P-gp and CYP3A from Splenda in rats is comparable to or greater than the increases found to reduce the bioavailability of some drugs in humans ([@R97]). Several studies suggested that rat data on P-gp kinetics might be extrapolated to humans ([@R366]; [@R173]). Co-administration of drugs that increase the expression of intestinal P-gp and/or CYP has emerged as an important factor in drug--drug interactions ([@R161]; [@R160]; [@R166]; [@R14]; [@R141]; [@R197]; [@R326]; [@R97]; [@R446]; [@R92]; [@R21]; [@R21]; [@R298]; [@R255]; [@R299]; [@R458]; [@R60]; [@R391]). The elevated expression of P-gp and CYP by consumption of sucralose is of particular concern for patients who take medications that are substrates of P-gp and CYP proteins. Overexpression of P-gp from anticancer agents such as anthracyclines (doxorubicin and daunorubicin) and *Vinca* alkaloids (vinblastine and vincristine) is associated with multidrug resistance; that is, elevated P-gp efflux may reduce intracellular concentrations of therapeutic drugs in neoplastic tissues ([@R137]; [@R102]; [@R260]; [@R138]). Overexpression of P-gp by two- to fivefold is typical in drug-resistant human tumors and hence clinically relevant in cancer treatment ([@R247]). Data suggest that the 2.43-fold (or 143.5%) rise in P-gp expression ([Table 1](#T1){ref-type="table"}) after daily consumption of Splenda with a sucralose dosage of 3.3 mg/kg/d (equivalent to two 12-oz soft drinks) may be clinically relevant.

METABOLIC FATE AND SAFETY PROFILE OF SUCRALOSE METABOLITES {#s16}
==========================================================

Metabolites of sucralose have been detected in the feces and urine of rats and humans by thin-layer chromatographic (TLC) methods, but the chemical identities of these metabolites have not yet been established ([@R356]; [@R320]). Thin-layer chromatograms (TLC) of methanolic fecal extracts following administration of ^14^C-sucralose to rats ([@R356]) and humans ([@R320]) suggested that sucralose is metabolized in the GIT. A comparison of TLC radiochromatographic profiles of methanolic fecal extracts following a single intravenous (iv) and a single oral administration of ^14^C sucralose in two rats is shown in [Figures 1a and 1b](#F1){ref-type="fig"}, respectively (from [@R356]). The profile in [Figure 1b](#F1){ref-type="fig"} (the peaks are enlarged to the right) from the rat that received oral ^14^C-sucralose yielded a broader trace that contained multiple, closely eluting peaks of approximately equal height when compared to the thinner profile with one peak from the rat that received the iv dose. The multiple peaks in the trace in [Figure 1b](#F1){ref-type="fig"} indicate the presence of at least two radioactive chemicals in the fecal material; that is, sucralose underwent metabolism and was not excreted unchanged in the feces. In addition, the R~f~ values (i.e., relative distance) of the peaks in [Figure 1b](#F1){ref-type="fig"} from the oral dose are shifted somewhat to the left of the R~f~ value of the putative sucralose peak from the IV dose in [Figure 1a](#F1){ref-type="fig"}. This suggests that at least one of the peaks in [Figure 1b](#F1){ref-type="fig"} represents a chemical other than sucralose itself. The rat that received the oral dose had been maintained on a sucralose-containing diet for 85 wk that, according to the findings of [@R3], would most likely have enhanced the expression of CYP. TLC radiochromatographic profiles of fecal extracts from a single human subject using two different solvents also indicate the presence of several peaks ([@R320]). Although TLC is a straightforward technique to separate component compounds in mixtures, it cannot be used to identify specific metabolites. Use of liquid chromatography--mass spectrometry (LC-MS) enables the chemical identification of sucralose metabolites. After the metabolites have been systematically identified, they can be evaluated for safety. Metabolites of drugs with exposures that are \>10% of the administered dose or systemic exposure are recommended for safety assessment by regulatory agencies ([@R321]).

![Thin-layer radiochromatographic profile of methanolic fecal extracts following both intravenous (iv) and oral administration of ^14^C-sucralose: (a) 0--24 h fecal sample from a male rat given an iv dose of ^14^C-sucralose (2 mg/kg); (b) 0--24 h fecal sample from a male rat maintained on a diet containing 30,000 ppm sucralose for 85 wk before receiving an oral dose of ^14^C-sucralose (100 mg/kg). An enlargement of the peak profile is given to the right. (TLC traces from [@R356]).](uteb16_399_f1){#F1}

Sims et al. (2008) reported that TLC scans of urine samples from rats given either an iv dose or oral administration of ^14^C-sucralose showed one large peak and several smaller peaks. They maintained that the large peak corresponded to unchanged sucralose while the smaller peaks were chromatographically more polar than sucralose. Historical reviews claimed that the small peaks are glucuronide conjugates of sucralose and not products of CYP metabolism in the liver ([@R142]; [@R271]; [@R143]). That is, the small peaks, which are chemically more polar than sucralose, have historically been considered glucuronide adducts of sucralose (with sucralose itself remaining intact) rather than actual metabolites. Several factors, however, limit these conclusions regarding the compounds excreted in the urine after ^14^C-sucralose administration. First, the statement that the large peak from urine in rats was a single compound cannot be confirmed because the TLC trace presented in a figure by [@R356] was truncated before reaching the crest. Second, the putative sucralose peak from 0--24 h urine samples after both iv and oral administration of ^14^C-sucralose had an R~f~ value that did not coincide with the R~f~ value from pure ^14^C-sucralose spiked into control rat urine. Third, the minor metabolites were reportedly resistant to hydrolysis by classical enzymatic techniques ([@R448]; [@R320]), and this raises questions about the identity of at least one of the minor components. If the metabolites found in the urine were indeed glucuronide conjugates, one would have anticipated hydrolysis by ß-glucuronidase.

The glucuronidation reaction, a detoxification pathway in which glucuronic acid is added to a substrate (such as sucralose), is catalyzed by the conjugating enzyme UDP-glucuronosyltransferase (UGT). The expression of UGT, like CYP3A isoforms and P-gp, is induced through the interaction of xenobiotics with the PXR ([@R59], [@R61]). Organochlorine compounds induce UGT with a variety of adverse effects, including alterations in thyroid function ([@R222]; [@R202], [@R201]; [@R459]). UGT activity also confers resistance to several chemotherapeutic drugs ([@R261]). Given the finding that P-gp and CYP3A are induced by sucralose ([@R3]) and that PXR is known to initiate P-gp and CYP3A induction, it is possible that activation of PXR may also induce UGT and affect the disposition of drugs that are substrates for glucuronidation.

The finding of multiple peaks in the TLC traces of fecal extracts from rats and humans is consistent with the finding by [@R3] that oral consumption of sucralose increases the expression of CYP isozymes in the intestine known to metabolize xenobiotics including drugs and other foreign substances. The identity of the metabolites has not yet been established, but known sucralose reaction products include its two hydrolysis products (e.g., the organochlorine monosaccharides 4-chloro-4-deoxygalactose \[4-CG\] and 1,6-dichloro-1,6-dideoxyfructose \[1,6-DCF\]; [@R142]), an unsaturated aldehyde of sucralose ([@R220]), and 3',6'-anhydro-4,1'-dichlorogalactosucrose, which is gradually produced under aqueous, alkaline conditions ([@R20]). Overall, the TLC and CYP findings in aggregate do not support the historical contention that sucralose is not metabolized in the GIT as claimed by [@R356] and [@R320] and in review papers by [@R142], [@R271], and [@R143].

EFFECT OF SUCRALOSE ON THE NUMBER AND RELATIVE PROPORTIONS OF DIFFERENT INTESTINAL BACTERIAL TYPES {#s17}
==================================================================================================

Studies of bacteria in culture media suggest that sucralose is not utilized as a growth substrate by microorganisms from the oral cavity ([@R466]) or from soil ([@R224]; [@R219], [@R220]). These findings raise the question of whether the presence of unabsorbed sucralose or its metabolites in the GIT affect the metabolic activity and composition of GIT microflora of humans and non-human animals. Gut microflora perform many useful functions, including fermentation of complex dietary carbohydrates with concomitant formation of short-chain fatty acids (SCFA), synthesis of vitamins (e.g., B and K), modulation of immune responses, regulation of postnatal gut development, inhibition of pathogens, absorption of calcium and magnesium, and metabolism of drugs ([@R8]; [@R75], [@R76]; [@R348]; [@R165]; [@R22]; [@R167]; [@R64]; [@R402]; [@R157]; [@R393]; [@R114]; [@R145]). Intestinal microbiota may modulate the expression of CYP, conjugating enzymes including UGT, and P-gp ([@R278]; [@R406]; [@R193]; [@R67]; [@R36]; [@R262]), which were reported to play a role in the disposition of sucralose. Intestinal bacterial composition was also shown to play a role in obesity ([@R96]; [@R232]; [@R405]; [@R404]).

Sucralose Administered as Splenda Reduces Bacterial Counts in the Gastrointestinal Tract and Alters Their Relative Proportions {#s18}
------------------------------------------------------------------------------------------------------------------------------

[@R3] found that sucralose delivered as Splenda reduced the numbers and altered the composition of microbiota in the GIT of male Sprague-Dawley rats. Fecal samples were collected each week during the 12 wk of treatment and for 12 wk of recovery from treatment for bacterial culture studies, quantification of fecal pH, and histopathological studies of the colon. Data showed that bacterial counts in the GIT from daily sucralose ingestion decreased progressively and monotonically in a methodical pattern during each successive week of sucralose treatment. [Table 3](#T3){ref-type="table"} shows the percent difference in bacterial counts for rats treated with sucralose relative to counts from control rats at the end of the 12-wk treatment period and at the end of the 12-wk recovery. The numbers of total anaerobes, bifidobacteria, lactobacilli, *Bacteroides*, clostridia, and total aerobic bacteria were significantly decreased at the end of the 12-wk treatment period with losses up to 79.7% for lactobacilli; there was no significant treatment-related effect on enterobacteria. These changes in bacterial counts were accompanied by intermittent incidences of unformed or soft feces as well as histopathological changes in the colon, including lymphocytic infiltrates into epithelium, epithelial scarring, mild depletion of goblet cells, and glandular disorganization. At the end of the 12-wk recovery period, the total anaerobes and bifidobacteria were still significantly lowered. Fecal pH increased during the treatment period (up to 7.4%) and remained significantly elevated at the end of the 12-wk recovery period. [@R3] concluded that sucralose (administered as Splenda) reduced the number of indigenous intestinal bacteria, with significantly greater suppression for the generally beneficial anaerobes (e.g., lactobacilli, and bifidobacteria), and with less inhibition for more detrimental bacteria (e.g., enterobacteria). Further, the numbers of total anaerobes remained partially suppressed after a 3-mo recovery period.

###### 

Percent Differences in Bacterial Counts for Sucralose-Treated Rats Relative to Untreated Control at the End of the 12-wk Treatment Period and at the End of the 12-wk Recovery

                                                        Sucralose dosage delivered daily in Splenda^[a](#T3-FN1){ref-type="table-fn"}^                   
  ----------------------------------------------------- -------------------------------------------------------------------------------- ------- ------- -------
  End of treatment^[d](#T3-FN4){ref-type="table-fn"}^                                                                                                    
  Total anaerobes                                       −49.8                                                                            −72.2   −73.7   −78.9
  Bifidobacteria                                        −36.9                                                                            −71.9   −76.0   −77.7
  Lactobacilli                                          −39.1                                                                            −62.8   −66.8   −79.7
  *Bacteroides*                                         −67.5                                                                            −75.6   −74.1   −77.5
  Clostridia                                            ---                                                                              −47.4   −55.3   −50.5
  Total aerobes                                         ---                                                                              −51.2   −51.2   −67.8
  Enterobacteria                                        ---                                                                              ---     ---     ---
  End of recovery[^e^](#T3-FN5){ref-type="table-fn"}                                                                                                     
  Total anaerobes                                       −53.9                                                                            −76.6   −56.7   −48.6
  Bifidobacteria                                        ---                                                                              −74.6   −61.1   ---
  Lactobacilli                                          ---                                                                              ---     ---     ---
  *Bacteroides*                                         ---                                                                              ---     ---     ---
  Clostridia                                            ---                                                                              ---     ---     ---
  Total aerobes                                         ---                                                                              ---     ---     ---
  Enterobacteria                                        ---                                                                              ---     ---     ---

*Note*. Data from [@R3].

Rats treated by oral gavage with Splenda containing sucralose doses of 1.1, 3.3, 5.5, and 11 mg/kg/d for 12 wk. Fecal samples were collected weekly over a 24-wk experimental period (12 wk of treatment and 12 wk of recovery).

Percent difference in the mean values of bacterial counts of Splenda/sucralose-treated groups relative to untreated controls. Numerical values are significantly different from the control group according to Student\'s *t*-test.

---Indicates not significantly different from the control group.

Percent difference after the 12-wk treatment.

Percent difference after 12-wk discontinuation of Splenda/sucralose treatment.

[@R51] claimed that the reduced numbers of microbiota reported by [@R3] were simply the result of normal variation. Three lines of evidence do not support this claim. First, the progressive and methodical weekly decrements in bacterial counts are not consistent with normal variation. If the decrements were due to normal variation for a single bacterial type such as bifidobacteria, the probability of systematic weekly reductions over 12 wk for a single dosage would be *p* \<.0002. Further, the likelihood that this systematic pattern in bacterial reduction occurred simultaneously for multiple bacterial types and sucralose dosages as a result of chance from normal biological variation is infinitesimal based on calculations using a Poisson distribution ([@R332]; [@R50]; [@R337]). Second, while changes in specific microbial species may occur over time in response to environmental factors and aging, many phylogenetic groups in the GIT such as *Bifidobacterium* are stable in both short-term intervals (*\<*1 yr) and long-term periods (\>10 yr) in humans ([@R315]). The average values of similarity for *Bifidobacterium* over different time spans reported by [@R315] were 0.92 at 3 mo, 0.91 at 2 yr, and 0.93 at 10 yr. In the [@R3] study, however, bifidobacteria were reduced by 71.9%, 76%, and 77.7% at dosages of 3.3, 5.5, and 11 mg/kg/d sucralose, respectively, and did not fully rebound during recovery. [@R3] also found decrements in *Bacteroides* (67.5%, 75.6%, 74.1%, and 77.5% at dosages of 1.1, 3.3, 5.5, and 11 mg/kg sucralose, respectively) that were statistically significant for all dosages. This perturbation of *Bacteroides* raises the possibility that sucralose may impact the stability of the entire bacterial ecosystem in the GIT because *Bacteroides* play a critical role in the stability and resilience of gut colonization ([@R229]). Third, the finding that total anaerobes remained partially suppressed after a 3-mo recovery period would not be expected if the changes from sucralose were simply random variation. Incomplete recovery of the bacterial composition in the GIT was also reported after exposure to antibiotics ([@R315]).

The reduction in the number of intestinal bacteria subsequent to sucralose ingestion in rats reported by [@R3] is consistent with the finding that sucralose exhibited antimicrobial activity against two oral bacteria involved in periodontal disease, *Aggregatibacter actinomycetemcomitans* and *Porphyromonas gingivalis*, in an in vitro study ([@R308]). Many chlorinated compounds such as triclosan, chlortetracycline, clotrimazole, clofazimine, chloramphenicol, and vancomycin in addition to sucralose are also known to possess antibacterial properties. Triclosan, like sucralose, is a trichlorinated compound and is used in many consumer products such as toothpaste; further, triclosan also enhances the expression of several CYP isozymes and interacts with PXR ([@R154]; [@R194]; [@R55]). Chronic exposure to chlorinated as well as unchlorinated compounds with antibacterial properties may lead to antibiotic resistance ([@R264]; [@R9]; [@R327], [@R328]), in which antimicrobial agents lose their initial efficacy over time.

Bacteria in Soil Metabolize Sucralose {#s19}
-------------------------------------

Although sucralose is apparently not used as a sole carbon source by bacteria for growth, it might be transformed microbiologically in soil and sewage ([@R224]; [@R219], [@R220]). [@R220], as noted previously, found that metabolism of sucralose by microorganisms in environmental samples generated numerous metabolic by-products, including an unsaturated aldehyde of sucralose, 1,6-DCF, and possibly the uronic acid of sucralose. Currently there is no evidence in the open scientific literature that sucralose is metabolized to 1,6-DCF or other aldehydes in vertebrate intestines. If 1,6-DCF and/or the unsaturated aldehyde are ultimately found to be by-products of intestinal metabolism of sucralose, this suggests possible mechanisms responsible for the reduced levels of bacteria in the GIT as reported by [@R3]. The sucralose hydrolysis product 1,6-DCF is an alkylating agent ([@R331]) and may damage bacterial DNA. Aldehydes are highly reactive molecules that adversely affect a wide spectrum of biological processes in bacterial as well as mammalian cells ([@R421]; [@R284]). Aldehydes such as glutaraldehyde, formaldehyde, and *ortho*-phthalaldehyde (OPA) possess antibacterial properties and have been used as disinfectants ([@R327], [@R328]; [@R118]).

Consequences of Reduction in Beneficial Bacterial Counts {#s20}
--------------------------------------------------------

Reductions and imbalances in the composition of intestinal bacteria play a role in numerous medical conditions, including allergies, gastric cancer, Crohn\'s disease, obesity, and inflammatory bowel disease (IBD) ([@R37]; [@R69]; [@R62]). [@R312], [@R313]) recently proposed that inhibition of intestinal microflora by sucralose is a causative factor in IBD based on epidemiological trends. Treatment of IBD includes the oral administration of probiotic bacteria such as lactobacilli and bifidobacteria ([@R41]); thus, the reduction in these probiotic bacterial types by sucralose may be detrimental to IBD patients. Overall, the scientific literature on ingestion of probiotic bacteria in foods such as yogurt suggests that the magnitude of the decrease in bacterial counts from sucralose is biologically significant. That is, the magnitude of the reduction in intestinal bacteria from sucralose administered in Splenda is similar to or greater than the magnitude of the increase (not decrease) in probiotic bacteria noted to produce significant health benefits including protection against infection, maintenance of the intestinal epithelial barrier, and treatment of IBD ([@R128]; [@R417]; [@R433]; [@R41]; [@R285]; [@R322]; [@R349]). Although concerns about potential adverse effects of sucralose on GIT bacteria were first raised several decades ago by the Joint FAO/WHO Expert Committee on Food Additives ([@R452]), the effects of sucralose on bacteria in the GIT in the general population and at-risk groups with vulnerable colonic ecosystems (e.g., IBD \[[@R374]\], diarrhea \[[@R189]\], immune deficiencies \[[@R168]\], and the elderly \[[@R449]; [@R290]\]) have not yet been performed.

POTENTIAL TOXICITY FROM HABITUAL SUCRALOSE INGESTION {#s21}
====================================================

Although several adverse behavioral effects including abnormal locomotion were reported in nonmammalian species after short-term low-dose sucralose exposure ([@R447]), no toxic effects were attributed to sucralose in historical single-dose or short-term sucralose studies in humans ([@R263]; [@R17]). However, the potential chronic effects of habitual sucralose consumption in humans have not been systematically investigated. Results from several recent studies raise a number of issues regarding potential safety of chronic sucralose intake in humans.

Genotoxicity {#s22}
------------

Sucralose is slowly hydrolyzed to its two constituent OC monosaccharides 4-CG and 1,6-DCF in acidic solutions (e.g., sodas) over time ([@R142]). 1,6-DCF was found to be weakly mutagenic in both the Ames test and the L5178Y TK+/− assay, and sucralose itself was found to be weakly mutagenic in the mouse lymphoma mutation assay ([@R159]; [@R6]). Other historical tests of genotoxicity were inconclusive, such as those for clastogenic activity of sucralose in a mouse micronucleus (MN) test and a chromosomal aberration (CA) test in cultured human lymphocytes ([@R6]). Sucralose also damaged DNA in gastrointestinal organs of the mouse in a comet test ([@R330]). The comet test is a single-cell gel electrophoresis assay that is used to detect DNA damage in various organs of experimental animals resulting from exposure to food additives, industrial chemicals, and pharmaceuticals ([@R361]; [@R301]). Two-year rodent bioassays found significant increases in the incidence of non-neoplastic findings; however, no evidence of elevated carcinogenic activity for either unprocessed sucralose (e.g., uncooked) or its hydrolysis products was reported in historical studies ([@R249], [@R250]; [@R159]). The clinical relevance of the findings from the Ames test, the L5178Y TK+/− assay, and the comet test for humans who consume sucralose on a continuous basis is not yet known.

Although the genome is the fundamental substrate of genetic content, it is the expression of genes that determines phenotype and clinical outcome, including any potential pathology. Genetic expression is shaped and regulated by epigenetic mechanisms that turn genes on and off without changing the underlying sequence of DNA ([@R158]; [@R170]). These mechanisms include altered DNA methylation (addition of a methyl group to the 5' position of the cytosine ring), histone modification (chemical alteration of histone proteins---the genetic packing material), and altered microRNA expression (posttranslational regulation of genes by targeting messenger RNA) ([@R170]). Studies using animal models and in vitro assays found that exposure to OC compounds as well as dietary factors induce epigenetic events. Organochlorine compounds including vinclozolin, methoxyclor, and dichloro- and trichloroacetic acid alter DNA methylation patterns ([@R389], [@R390]; [@R12]; [@R468]; [@R147]). Vinclozolin was reported to induce persistent epigenetic reprogramming that may be transmitted transgenerationally (Stouder and

[@R369]; [@R469]). Further, dietary factors have also been implicated in epigenetic changes ([@R53]; [@R422]; [@R259]; [@R109]). It is not yet known whether epigenetic events might be induced by habitual use of the OC sweetener sucralose or its hydrolysis product (and alkylating agent) 1,6-DCF in a dietary regimen.

Safety of Sucralose That Has Been Heated {#s23}
----------------------------------------

Recently, there has been renewed scientific interest in the safety of by-products generated by sucralose at elevated temperatures. Historically, sucralose was reported to be heat stable at temperatures used in cooking ([@R20]; [@R267]). However, this conclusion is not supported by data presented by [@R20] nor is it consistent with thermal degradation data from three other independent labs ([@R176]; [@R177]; [@R18]; [@R314]). [@R20] incorporated radioactive sucralose (^14^C-sucralose) into recipes for yellow cake, cookies, and graham crackers. After baking, the radio-labeled material was extracted from the baked goods and analyzed by TLC. Although the authors concluded that no peaks other than sucralose were detected in the TLC scans of the recovered material, examination of the TLC trace of an extract from cookies shows multiple, closely eluting peaks that suggest thermal degradation ([@R314]; [@R331]; [@R332]).

Subsequent to the publication by [@R20], [@R176] and [@R177] studied the thermal decomposition of sucralose in aqueous solutions at pH 3, 7, and 11 heated to 100, 140, and 180°C for 1 h. Data showed that the stability of sucralose decreased as the temperature and pH increased; at 180°C sucralose completely degraded at all pH levels with the release of chloride ions. In addition, [@R177] analyzed the volatile compounds released and concluded that dehydrochlorination steps accompanied their production. [@R18] used thermo-analytic techniques to study the effect of temperature on the stability of sucralose. They concluded that thermal decomposition of sucralose commences at 119°C with liberation of HCl and water. More recently, [@R314] raised new concerns about the stability and safety of sucralose in heated applications. Like [@R177] and [@R18], [@R314] concluded that sucralose undergoes thermal degradation. Further, [@R314] found that chloropropanols were generated when sucralose was heated in the presence of glycerol. Chloropropanols comprise a group of contaminants that include known genotoxic, carcinogenic, and tumorigenic compounds ([@R34]; [@R63], [@R403]; [@R343]; [@R453]). [@R314] concluded that "caution should be exercised in the use of sucralose as a sweetening agent during baking of food products containing glycerol and or lipids due to the potential formation of toxic chloropropanols." Other chlorinated compounds including dibenzo-*p*-dioxins and dibenzofurans, dioxin-like polychlorinated biphenyls, and polychlorinated naphthalenes were also generated by heating sucralose in the presence of foods ([@R87], [@R88]; [@R457]). Overall, these studies indicate that sucralose is not stable at elevated temperatures, and that the compounds generated were affected by the other ingredients in the mixture.

Potential for Bioaccumulation {#s24}
-----------------------------

Many OC compounds tend to bioaccumulate over time in a variety of animal species and tissue types ([@R365]; [@R344]; [@R441]; [@R13]). For this reason, information on the potential bioaccumulation of sucralose and its metabolites is vital for determining the chronic safety of this OC sweetener. Sucralose is an amphiphilic molecule that is comprised of hydrophobic domains (-C-CH2Cl) as well as hydrophilic domains (hydroxyl groups); that is, it possesses both lipophilic and hydrophilic properties. However, [@R143] claimed that sucralose is "not lipophilic, and not expected to be bioaccumulative." This publication failed to consider the breadth of the scientific literature or provide adequate data to support their claim. The contention by [@R143] that sucralose is not lipophilic conflicts with the following lines of scientific evidence.

### Basic Principles of Chemistry {#s25}

The scientific rationale for the synthesis of sucralose was the basic principle that incorporation of halogen atoms into a lead compound results in analogs with increased lipophilicity and hence improved penetration of lipid membranes and tissues, elevated bioavailability, and potential for enhanced potency depending on the sites of the halogen substituents in the derived molecule ([@R394]).

### Publications by the Discoverers of Sucralose {#s26}

[@R171] stated, "The introduction of chloro groups into the sucrose molecule clearly increases its lipophilicity, an important factor in sweetness intensification." Further, they specifically underscored the amphiphilic nature of sucralose (termed 1',4,6'-trichlorogalactosucrose in early publications) by stating that it had "the optimum hydrophilic-lipophilic structure" of the chlorinated sweeteners that they synthesized. In the case of disaccharides, [@R172] reported that selective replacement of certain hydrophilic hydroxyl groups with "hydrophobic halogeno substituents" enhanced sweetness and led to the discovery of a "galacto-sucrose" compound ultimately named sucralose.

### Historical Publications Relevant to the Solubility of Sucralose {#s27}

[@R142] noted that a fraction of ingested sucralose is "absorbed from the upper part of the gastrointestinal tract by passive diffusion" in humans and animal models (up to 35--40%, depending on the species). That is, sucralose was sufficiently lipophilic to diffuse through the hydrophobic interior of the phospholipid membrane bilayers of enterocytes and sufficiently water-soluble to be distributed in the systemic circulation---that is, sucralose is an amphiphilic molecule. The passive diffusion of sucralose through membranes of enterocytes may be explained by the fact that phospholipids are themselves amphiphilic molecules that arrange themselves into bilayers with their lipophilic chains toward the inside of the bilayer and their polar groups towards the surrounding aqueous medium. Other amphiphilic molecules, such as cholesterol and glycolipids, also interact with this lipophilic bilayer. The polar nature of brush border membranes is one factor that explains in part why log P (log of the octanol/water partition coefficient) of a compound was found to be an unreliable predictor of intestinal absorption ([@R412]; [@R199]); that is, the polarities of the brush border membrane and octanol are different.

The amphiphilic nature of sucralose is reflected in the choice of solvents such as methanol, butanol, diethylether, ethyl acetate, and ethyl methyl ketone used historically to recover sucralose from excreta ([@R356]; [@R320]). These particular solvents are often used to extract lipid components from mixtures ([@R316]; [@R132]; [@R251]; [@R54]; [@R74]; [@R238]). The fact that sucralose is readily soluble in alcohols was corroborated by others ([@R28]; [@R11]; [@R234]).

### Possible Role of Glucuronidation in Sucralose Metabolism {#s28}

Glucuronide conjugates are reportedly formed during sucralose metabolism ([@R142]; [@R320]; [@R448]). Although certain aspects of the claim of glucuronidation are unresolved as noted earlier, this would provide further evidence for the lipophilicity of sucralose. The process of glucuronidation would render xenobiotics (e.g., sucralose and its metabolites) more water-soluble by linking them to glucuronic acid.

### Lipophilicity Requirements for Interaction With P-gp and CYP {#s29}

Verification of the amphiphilic nature of sucralose comes from the finding of [@R3] that sucralose interacts with P-gp and CYP isozymes. This interaction with P-gp and CYP could not have occurred unless sucralose had diffused through domains of the phospholipid membrane bilayer of enterocytes. A requisite property of xenobiotic compounds to interact with P-gp and CYP is that they are amphiphilic or lipophilic ([@R122]; [@R252]; [@R461]; [@R431]).

### Recognition of Amphiphilic Properties by Regulatory Agencies {#s30}

The [@R6] and the [@R104] approvals of sucralose for use in both fat- and water-based products reflect their understanding of the amphiphilic nature of sucralose.

The potential bioaccumulation of sucralose and its metabolites after long-term exposure in the presence and absence of P-gp and CYP inhibitors has not yet been investigated. Three lines of evidence suggest, however, that bioaccumulation of sucralose and/or its metabolites may occur. First, the expression of P-gp and CYP reported by [@R3] was elevated 12 wk following withdrawal from sucralose (at 5.5 mg/kg/d and 11 mg/kg/d) (see [Table 1](#T1){ref-type="table"}). This finding suggests that bioaccumulated sucralose or its metabolites may have been released during the 12-wk recovery because P-gp and CYP typically return to baseline after induction within 1--2 wk ([@R183]; [@R350]). Further, [@R3] also observed that bacterial counts and fecal pH were still significantly affected in sucralose-treated animals compared with controls at the conclusion of the 12-wk recovery period. The second line of evidence is that excretion of sucralose and/or its metabolites was prolonged in two of 8 unmedicated human subjects who consumed a single oral dose of 1 mg/kg ^14^C-sucralose which is less sucralose than in one 12-oz drink ([@R320]). Approximately 12% of the radioactivity had not yet been excreted 5 d following ^14^C-sucralose administration. Although this prolonged GIT transit time (beyond the norm of ∼1--3 d in healthy individuals) may be attributed to individual variation, it may also result from bioaccumulation. The third line of evidence is based on the temporal sensory profile of sucralose that has a delayed onset of sweetness and a lingering of sweetness perception when ingested into the oral cavity. This temporal profile is characteristic of sweetener compounds that undergo nonspecific binding to sites other than (or distinct from) the taste receptor that binds the sweetener ([@R93]; [@R94]). Nonspecific binding is a factor known to play a role in bioaccumulation ([@R15]). Future studies need to be performed to determine whether the co-administration of sucralose (and/or its metabolites and breakdown products) with drugs that are inhibitors of P-gp or CYP enhances the potential for bioaccumulation because sucralose, in the absence of inhibitors, is normally effluxed by P-gp and metabolized by CYP in the gut.

Significant Biological Effects Occur From Sucralose Ingestion Below the ADI {#s31}
---------------------------------------------------------------------------

As noted earlier, the FDA established an ADI for humans at 5 mg/kg/d in 1998 based on toxicity studies in the rat. The ADI is an estimate of the maximum amount of a substance that a person can ingest daily over a lifetime without harmful effects. Prior to the derivation of the rat-based ADI, the FDA reviewed studies of sucralose and/or its hydrolysis products in several animal species including rat, mouse, dog, rabbit, and monkey for potential toxicological effects (see [Table 4](#T4){ref-type="table"} for published accounts of some adverse effects at high doses). After their review of these animal studies submitted by the petitioner, the FDA concluded that the appropriate animal model for establishing an ADI for sucralose was the rat. The FDA determined that the no-observed-effect level (NOEL) in rat was 500 mg/kg/d; this number was based on a combined chronic toxicity/carcinogenicity study, a diet restriction study, and a 26-wk gavage study. After applying a 100-fold safety factor, the ADI was set at 5 mg/kg/d. The ADI adopted by the Scientific Committee on Food in Europe ([@R342]) was determined to be 15 mg/kg/d.

###### 

Representative Examples of Adverse Effects Reported in Toxicity Studies of Sucralose and Its Hydrolysis Products at High Dosages

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference         Species (and number of animals affected when given)                        Adverse effect
  ----------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@R111])          Mouse (1 of 10)                                                            Death during 21 d study: dose (150 mg/kg/d of sucralose hydrolysis products administered by gavage)

                    Mouse (2 of 10)                                                            Deaths during 21 d study: dose (1000 mg/kg/d of sucralose hydrolysis products administered by gavage)

                    Mouse (increased frequency)                                                Unkempt coats during 21 d study: dose (500 and 1000 mg/kg/d of sucralose hydrolysis products administered by gavage)

                    Mouse (1 of 10)                                                            Slow righting reflex (neurological finding) during 21 d study: dose (500 mg/kg/d of sucralose hydrolysis products administered by gavage)

  [@R249]           Mouse                                                                      Lower erythrocyte counts in females after 104 wk: dose (3% dietary sucralose); chronic nephropathy in females and chronic inflammation of the liver in males: dose (3.0% dietary sucralose); degeneration of the testicular tubular germinal epithelium: dose (0.3--3.0% dietary sucralose)

  [@R111])          Marmoset                                                                   Altered salivary responses during second half of 28 d study: dose (1000 mg/kg/d of sucralose and its hydrolysis products administered by gavage)

                    Marmoset (2 of 3)                                                          Depressed postural reactions at 13 d into a 28 d study: dose (1000 mg/kg/d of sucralose administered by gavage); reactions reportedly remitted by d 27

                    Marmoset (2 of 3)                                                          Depressed postural responses on d 27 of 28 d study: dose (1000 mg/kg/d of sucralose hydrolysis products administered by gavage)

  [@R208]           Rabbit, pregnant                                                           Gastrointestinal tract disturbances, such as peri-anal soiling, scouring and caecal enlargement: dose (750 to 1000 mg/kg/d of sucralose administered by gavage)

                    Rabbit, presumed pregnant (7 of 15)                                        Mild to severe gastrointestinal distress during d 6 to 19 of gestation: dose (700 mg/kg/d administered by gavage)

  [@R208]); [@R6]   Rabbit, pregnant (12 of 13 deaths occurred in sucralose-treated animals)   Deaths in four groups of 16 to 18 pregnant rabbits: dose (0, 175, 350, and 700 mg/kg/d administered by gavage during d 6 to 19 of gestation); deaths of 11 rabbits (1 control, 4 receiving 175 mg/kg/d group, 2 receiving 350 mg/kg/d group, and 4 receiving 700 mg/kg/d) were not attributed to sucralose by the experimenters although 10 of these 11 deaths occurred during treatment with sucralose. Only two deaths at 700 mg/kg/d were attributed to sucralose by the experimenters.

                    Rabbit (4 of 9)                                                            Abortions: dose (700 mg/kg/d administered by gavage)

  [@R130]           Rat                                                                        Decrease in total leukocyte and lymphocyte counts of females after 4 wk: dose (5.0% dietary sucralose)\
                                                                                               Decrease in alanine aminotransferase (ALT) after 4 wk: dose (5.0% dietary sucralose; also 2.5% in females)\
                                                                                               Decreased serum phosphorus in all male treatment groups after 4 wk: dose (1 %, 2.5%, and 5% dietary sucralose)\
                                                                                               Increased urinary excretion of calcium and magnesium in females: dose (5% dietary sucralose)\
                                                                                               Dose-related increase in cecal weight with and without contents: dose (2.5 and 5.0% dietary sucralose)\
                                                                                               Decreases in organ weights including spleen, thymus, and heart after 8 wk: dose (5.0% dietary sucralose)

  [@R249]           Rat                                                                        Decrease in alanine aminotransferase (ALT) activity after 11, 38, 51, 77 and 103 wk of treatment; dose (3% dietarysucralose) Thyroxine levels were decreased in male rats at 11 wk in a dose-dependent manner: dose (0.3% to 3.0% dietary sucralose)\
                                                                                               Higher phosphorus excretion after *77* wk: dose (0.3% to 3.0% dietary sucralose)\
                                                                                               Non-neoplastic findings in females including renal pelvic epithelial hyperplasia, renal pelvic mineralization, and adrenal cortical haemorrhagic degeneration; cataracts in males: dose (3.0% dietary sucralose)

  [@R130])          Rat                                                                        Increased body weight-relative kidney weights during 28-d study: dose (3000 mg/kg/d by gavage)\
                                                                                               Increased cecum weights during 28-d study: dose (1500 and 3000 mg/kg/d by gavage)\
                                                                                               Elongated or distended caecum during 28-d study: dose (1500 and 3000 mg/kg/d by gavage)

  [@R130]           Dog                                                                        Lower lymphocyte counts at 3 mo: dose (1 % dietary sucralose); lower lymphocyte counts at 6 mo; dose (1 % and 3% dietary sucralose); lower lymphocyte counts at 12 mo; dose (0.3% dietary sucralose)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Subsequent data from [@R3] described earlier in this review indicate that the NOEL for sucralose in rats is actually much lower than the ADI set by the FDA and EU. Significant alterations of the rat microbiome occurred at 1.1 mg/kg/d sucralose (administered as Splenda), and significant increases in intestinal P-gp and CYP were observed at 3.3 mg/kg/d. If the disposition of sucralose in rat and human is the same, then significant biological effects would be expected in humans below the ADI. These effects may include intestinal disorders such as IBD as suggested by [@R312], [@R313]), in addition to altered bioavailability of drugs due to enhanced expression of P-gp and CYP. Additional research is required to determine whether the metabolites of sucralose generated in humans and rats are identical and in the same ratio. If not, then the historical rat safety assessment of sucralose ([@R130]; [@R250]) may not be fully applicable to humans.

Positive Allosteric Modulators Ramp Up Physiological Responses to Sucralose {#s32}
---------------------------------------------------------------------------

Positive allosteric modulators (PAMs) have recently been discovered that increase the function and biological activity of G protein-coupled receptors (GPCRs) including the T1R2/T1R3 sweet taste receptor ([@R94]). Co-administration of PAMs with sucralose ([@R347], [@R346]; [@R470]) was shown to amplify activity and functioning of T1R2/T1R3. PAMs are chemicals that interact with geographical regions of the receptor that are topographically distinct from active "orthosteric" binding sites. Allosteric molecules subtly change the conformation of a receptor and allow a ligand (e.g., sucralose) to bind more effectively to its active site ([@R445]). An example of a PAM that is currently used as a sucralose enhancer in the food supply is the chemical 4-amino-5,6-dimethylthieno\[2,3-d\]pyrimidin-2(1H)-one (ADTP) ([@R347]; [@R230]; [@R358]; [@R47]; [@R94]). ADTP significantly enhanced responses to sucralose in intact cells, in which activation of the human sweet taste receptor coupled to a G protein ultimately led to a net rise in intracellular calcium mobilization. It also enhanced the perceived sweetness of sucralose by up to eightfold in humans as determined by behavioral/sensory responses even though ADTP has no sweet taste of its own ([@R347]).

ADTP, which has a Chemical Abstract Service Registry number of 121746-18-7, was added to the GRAS (Generally Regarded as Safe) list ([@R230]; [@R358]; [@R47]) after review by the Expert Panel of the Flavor and Extract Manufacterers Association (FEMA), an organization of flavor manufacturers and ingredient suppliers that is responsible for the GRAS evaluation program and oversees safety assessments of flavoring compounds added to the food supply ([@R357]). The European Food Safety Authority ([@R99]) panel also gave a positive assessment regarding addition of ADTP to the European food supply but noted that "it is not possible to conclude" that ADTP "would be metabolised to innocuous products at the reported levels of intake as flavouring substances" The panel also suggested that additional exposure and toxicological data might be necessary ([@R99]). A WHO report ([@R455]) noted that several clinical chemistry parameters were altered by ADTP, including increased creatinine, total chlolesterol, total triglycerides, glucose, and protein levels, but considered these changes to be an adaptive response to treatment rather than toxicologically important. Further studies are needed to determine whether sucralose in the presence of PAMs including ADTP induces clinically significant alterations in physiological processes because allosteric modulation of GPCRs may contribute to unexpected clinical outcomes ([@R450]).

FINAL COMMENTS AND CONCLUSIONS {#s33}
==============================

Although sucralose is utilized globally as a sweetener in thousands of food and beverage products, further scientific research is warranted in several areas due to the following potentially significant findings:

1.  *Sucralose alters metabolic parameters and its chronic effects on body weight are unknown*. Sucralose modulates glucose transport and insulin secretion in rodents ([@R253]; [@R244]; [@R274]). It was reported to increase glucose and insulin levels in obese women ([@R300]) and, when given together with ace-K, to enhance GLP-1 secretion in healthy individuals and persons with type 1 diabetes ([@R47]).

2.  *Sucralose alters P-gp and CYP expression*. Sucralose (delivered as Splenda) increased the expression of the efflux transporter P-gp and CYP metabolizing enzymes that control the bioavailability of drugs ([@R3]). Significant elevation in the expression of P-gp and CYP occured at dosages approved by regulatory agencies, including the FDA ([@R6]) and the [@R104]. The magnitude of enhanced expression of P-gp and CYP3A4 produced by sucralose in rats is similar to that induced by the herbal antidepressant St. John\'s wort ([@R97]) that interferes with bioavailability of therapeutic drugs for heart failure, HIV infection, and organ rejection ([@R197]; [@R304]; [@R326]; [@R97]; [@R397]).

3.  *The metabolic fate and health profile of sucralose metabolites are currently unknown*. Metabolites of sucralose were detected in the feces and urine of rats and humans using TLC ([@R356]; [@R320]), but the identity and health profile of these metabolites have not yet been determined. The detection of metabolites of sucralose by TLC in the GIT and the increased expression of intestinal CYP reported by [@R3] do not support claims by [@R143] and [@R51] that sucralose is "stable in vivo" and eliminated "unchanged" in the feces. Thus, the pharmacokinetics and safety of sucralose and its metabolites need to be revisited to determine how sucralose is handled by the body.

4.  *Sucralose alters indigenous bacterial balance in the GIT*. Sucralose (delivered as Splenda) reduced the number of indigenous bacteria in the GIT with significantly greater suppression for the generally beneficial anaerobes (e.g., lactobacilli, bifidobacteria) and with less inhibition for more detrimental bacteria (e.g., enterobacteria). Further, the numbers of total anaerobes did not return to baseline after a 3-mo recovery period ([@R3]). Alterations in the number and composition of bacteria were accompanied by elevation of fecal pH and histopathological changes in intestinal epithelial barrier. Given that alterations in gut microflora contribute to numerous medical conditions ([@R145]; [@R157]; [@R404]), further investigation of the impact of sucralose on gut microflora is warranted.

5.  *Numerous toxicological issues regarding long-term exposure to sucralose are unresolved*. Several issues that warrant additional investigation to determine their clinical relevancy include potential damage to DNA ([@R330]), generation of chloropropanols during baking ([@R314]), and potential epigenetic alterations, particularly for the sucralose hydrolysis product 1,6-DCF which is an alkylating agent. The possibility of bioaccumulation of sucralose and/or its metabolites in the presence and absence of medications has not yet been studied. The health effects of co-administration of sucralose with the taste enhancer ADTP are not known.

Finally, artificial sweeteners, including sucralose, are regulated as food additives and are not required to undergo screening for interactions with drug-metabolizing enzymes prior to approval. While food additives do undergo toxicology, teratogenicity, and carcinogenicity testing, the screening overall is less stringent than that required for drugs ([@R53]; [@R46]; [@R321]). Further, thousands of flavoring substances are excluded from mandatory premarket approval by the U.S. FDA and reach the food supply after review by the Expert Panel of the Flavor and Extract Manufacturers Association ([@R358]). Given the fact that sucralose ([@R3]) and certain foods and herbs interact with drug-metabolizing enzymes and transporters ([@R281]; [@R474]), guidelines need to be developed for the appropriate use and labeling of food ingredients based on their pharmacokinetic parameters and biological activity to ensure the safety of the food supply for all segments of the population.

[^1]: This research was supported in part by the Intramural Research Program of the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
